ING, PALI and FNCH Among Pre-market Losers
Seeking AlphaApr 24 08:45 ET
Express News | Silo Pharma Shares Are Trading Higher After the Company Announced Intranasal Delivery of SPC-15 Showed a 'Rapid and Effective' Drug Exposure for PTSD Therapy
Moomoo 24/7Apr 23 08:18 ET
Express News | Silo Pharma: Non-Glp Study to Be Followed by Pind Study and Then Glp Study, Both Slated to Commence in 2024
Moomoo 24/7Apr 23 08:15 ET
Express News | Silo Pharma Inc: Intranasal Delivery of Spc-15 Shows Rapid and Effective Drug Exposure for Ptsd Therapy
Moomoo 24/7Apr 23 08:15 ET
Express News | Silo Pharma Announces Positive Results for Intranasal Ptsd Treatment
Moomoo 24/7Apr 23 08:15 ET
ATUS, ATHE and GRFS Among Pre-market Losers
Seeking AlphaApr 11 08:16 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersEliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. Rallybio (NASDAQ:
BenzingaApr 11 08:10 ET
Silo Pharma Slips 13% After Announcing Plans To Buy Alzheimer's Disease Therapeutic License
RTTNewsApr 10 10:05 ET
Silo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia University
RTTNewsApr 10 09:03 ET
Silo Pharma Set To Acquire Exclusive Licensing For Promising Alzheimer's Disease Therapeutic; SPC-14 Shows Cognitive And Stress Reduction Benefits In Preclinical Models
SPC-14 shows cognitive and stress reduction benefits in preclinical modelsSARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental s
BenzingaApr 10 08:11 ET
Citizens And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
BenzingaApr 9 09:03 ET
Silo Pharma(SILO.US) Officer Buys US$1,988 in Common Stock
$Silo Pharma(SILO.US)$ Officer Weisblum Eric purchased 1,000 shares of common stock on Apr 4, 5, 2024 at an average price of $1.99 for a total value of $1,988.Source: Announcement What is statement of
moomoo NewsApr 8 16:42 ET
Silo Pharma CEO Buys Shares Worth $1,988
InvestingApr 8 16:04 ET
Express News | Silo Pharma Approved Extension Of Previously Announced Stock Repurchase Program Authorizing Purchase Of Up To $1M Common Stock Until April 30
Moomoo 24/7Apr 5 16:14 ET
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
BenzingaApr 2 07:39 ET
Silo Pharma(SILO.US) Officer Buys US$8,712.52 in Common Stock
$Silo Pharma(SILO.US)$ Officer Weisblum Eric purchased 4,508 shares of Common Stock on Mar 28, Apr 1, 2024 at an average price of $1.93 for a total value of $8,712.52.Source: Announcement What is stat
moomoo NewsApr 1 18:56 ET
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr
BenzingaMar 30 08:57 ET
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
BenzingaMar 29 12:43 ET
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
BenzingaMar 20 14:49 ET
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO)
GlobeNewswireMar 20 08:30 ET
No Data
No Data